Lantern Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tavocept (dimesna) / BioNumerik, Lantern Pharma
HARMONIC, NCT05456256: A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma

Recruiting
2
90
Japan, US, RoW
LP-300, Tavocept, BNP7787, Dimesna, Pemetrexed, Alimta, Pemfexy, Carboplatin, Paraplatin
Lantern Pharma Inc.
Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
12/25
06/26
hydroxyureamethylacylfulvene (STAR-001) / Lantern Pharma
LTRN184-1AST23-1, NCT05933265: Study of LP-184 in Patients with Advanced Solid Tumors

Recruiting
1/2
175
US
LP-184, Spironolactone, Olaparib
Lantern Pharma Inc.
Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
02/25
09/25
irofulven-1 (LP-100) / Lantern Pharma, Eisai
2019-002071-34: Allocation of patients with relapse of cancer to treatment with new drugs based on tumor biopsy

Not yet recruiting
2
40
Europe
LiPlaCis, Irofulven, 2X-121, Concentrate for dispersion for infusion, Concentrate for solution for infusion, Capsule, hard
Vejle Hospital, Vejle Hospital, Oncology Venture
Breast cancer Ovarian cancer Lung cancer Colorectal cancer Prostate cancer Pancreatic cancer, Breast cancer Ovarian cancer Lung cancer Cancer of the colon and rectum Prostate cancer Pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
NCT03643107 / 2017-003549-72: Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Active, not recruiting
2
27
Europe
Irofulven, Prednisolone 10 mg
Allarity Therapeutics, Smerud Medical Research International AS, Lantern Pharma Inc.
Metastatic Castration-Resistant Prostate Cancer Patients
10/21
08/24
LP-284 / Lantern Pharma
NCT06132503: Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients with Relapsed or Refractory Lymphomas and Solid Tumors

Recruiting
1
110
US
LP-284
Lantern Pharma Inc.
Relapsed or Refractory Lymphomas, Advanced Solid Tumor
11/28
11/28
Cp-ADC / Lantern Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tavocept (dimesna) / BioNumerik, Lantern Pharma
HARMONIC, NCT05456256: A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma

Recruiting
2
90
Japan, US, RoW
LP-300, Tavocept, BNP7787, Dimesna, Pemetrexed, Alimta, Pemfexy, Carboplatin, Paraplatin
Lantern Pharma Inc.
Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
12/25
06/26
hydroxyureamethylacylfulvene (STAR-001) / Lantern Pharma
LTRN184-1AST23-1, NCT05933265: Study of LP-184 in Patients with Advanced Solid Tumors

Recruiting
1/2
175
US
LP-184, Spironolactone, Olaparib
Lantern Pharma Inc.
Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
02/25
09/25
irofulven-1 (LP-100) / Lantern Pharma, Eisai
2019-002071-34: Allocation of patients with relapse of cancer to treatment with new drugs based on tumor biopsy

Not yet recruiting
2
40
Europe
LiPlaCis, Irofulven, 2X-121, Concentrate for dispersion for infusion, Concentrate for solution for infusion, Capsule, hard
Vejle Hospital, Vejle Hospital, Oncology Venture
Breast cancer Ovarian cancer Lung cancer Colorectal cancer Prostate cancer Pancreatic cancer, Breast cancer Ovarian cancer Lung cancer Cancer of the colon and rectum Prostate cancer Pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
NCT03643107 / 2017-003549-72: Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Active, not recruiting
2
27
Europe
Irofulven, Prednisolone 10 mg
Allarity Therapeutics, Smerud Medical Research International AS, Lantern Pharma Inc.
Metastatic Castration-Resistant Prostate Cancer Patients
10/21
08/24
LP-284 / Lantern Pharma
NCT06132503: Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients with Relapsed or Refractory Lymphomas and Solid Tumors

Recruiting
1
110
US
LP-284
Lantern Pharma Inc.
Relapsed or Refractory Lymphomas, Advanced Solid Tumor
11/28
11/28
Cp-ADC / Lantern Pharma
No trials found

Download Options